Domainex wins Best CRO at OBN Awards

Domainex wins Best CRO at OBN Awards

Saffron Walden, UK, 14th June 2021 / Sciad Newswire / Domainex is delighted to announce that it has been awarded ‘Best CRO’ at the OBN Awards 2020. Dr Tom Mander, CEO, Dr Ray Boffey, Executive Director of Medicines Research, and Dr Cat Stace, Director of Business Development, attended the postponed awards ceremony in London on Friday 11^th June 2021.

Over the past year, Domainex has made significant investment in new technology to support its clients’ research needs and secured an out-licencing deal with Invivoscribe Inc. of a therapeutic drug candidate to treat patients with multiple myeloma. The company grew its top line by ~45% in 2020 and welcomed over 30 new colleagues to its team to further extend its drug discovery offering, despite the challenges faced as a result of the pandemic. To support this growth, Domainex launched a new brand and website, and has seen exciting changes in leadership including Dr Tom Mander moving from COO to CEO, Dr Eddy Littler returning to the company as Non-Executive Chairman, David Cronk joining as Chief of Staff and Dr Ray Boffey’s promotion to Executive Director of Medicines Research.

This progress, along with the continued hard work and excellence of all team members, has allowed Domainex to expand the high-quality services it offers to its clients and partners on a 7-day/week basis. The ability to create and deliver tailor-made drug discovery programmes has helped to build Domainex’s reputation as a reliable and innovative CRO of the highest standard.

OBN acknowledged Domainex’s achievements and innovations in the life sciences industry as part of a continued effort to meet previously unmet clinical needs. Furthermore, it recognised the strong leadership, excellent customer-care, and collaborative and integrated work ethos. Presenting Domainex with the award, the judges commented: “The winner in this category were the only finalist that named their customers and provided excellent customer testimonials. They have their own product programme licensed out and have a clear approach to their robust and effective strategy.”

Tom Mander, CEO of Domainex, commented, “Customer focus is a core value that we are incredibly proud of at Domainex, and we are delighted that this has been recognised by OBN with this award. I would like to thank our team for their consistent hard work and positive can-do approach while facing the additional challenges created by the pandemic. It is the amazing attitudes of our team that allows Domainex to offer high quality services and remain a leader in the field of drug discovery.”

Congratulations to the other finalists and thank you to OBN for arranging the awards and for its continued commitment to supporting such an important industry.